| P50 | author | Chih-Cheng Wu | Q57016334 |
| P2093 | author name string | Der-Cherng Tarng | |
| | Szu-Chun Hung | |
| | Ko-Lin Kuo | |
| P2860 | cites work | The aryl hydrocarbon receptor-activating effect of uremic toxins from tryptophan metabolism: a new concept to understand cardiovascular complications of chronic kidney disease | Q28382992 |
| | Indoxyl Sulfate Induces Leukocyte-Endothelial Interactions through Up-regulation of E-selectin | Q30497600 |
| | Chronic kidney disease-induced cardiac fibrosis is ameliorated by reducing circulating levels of a non-dialysable uremic toxin, indoxyl sulfate | Q31076633 |
| | Subtotal nephrectomy impairs ischemia-induced angiogenesis and hindlimb re-perfusion in rats | Q33241242 |
| | Role of the Gut Microbiome in Uremia: A Potential Therapeutic Target | Q33613115 |
| | Expansion of urease- and uricase-containing, indole- and p-cresol-forming and contraction of short-chain fatty acid-producing intestinal microbiota in ESRD. | Q33725646 |
| | Cardiovascular disease relates to intestinal uptake of p-cresol in patients with chronic kidney disease | Q33780255 |
| | Impact of aortic stiffness on survival in end-stage renal disease | Q33861423 |
| | p-Cresol and cardiovascular risk in mild-to-moderate kidney disease | Q33944858 |
| | The uremic toxicity of indoxyl sulfate and p-cresyl sulfate: a systematic review | Q34103477 |
| | Cardiovascular disease in chronic renal insufficiency | Q34105300 |
| | Effect of increasing dietary fiber on plasma levels of colon-derived solutes in hemodialysis patients | Q34124697 |
| | Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Preventi | Q34272627 |
| | Indoxyl Sulfate–Induced Endothelial Dysfunction in Patients with Chronic Kidney Disease via an Induction of Oxidative Stress | Q34497254 |
| | p-Cresyl sulphate and indoxyl sulphate predict progression of chronic kidney disease | Q34593224 |
| | Association of indoxyl sulfate with heart failure among patients on hemodialysis | Q34828638 |
| | The gut microbiome, kidney disease, and targeted interventions | Q35042986 |
| | Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study | Q35116672 |
| | Colonic contribution to uremic solutes. | Q35210230 |
| | The cardiovascular effect of the uremic solute indole-3 acetic acid | Q35228517 |
| | Uremic retention solute indoxyl sulfate level is associated with prolonged QTc interval in early CKD patients | Q35495467 |
| | Uremic serum and solutes increase post-vascular interventional thrombotic risk through altered stability of smooth muscle cell tissue factor | Q35532690 |
| | The Influence of CKD on Colonic Microbial Metabolism | Q35786047 |
| | Microbiota-Derived Phenylacetylglutamine Associates with Overall Mortality and Cardiovascular Disease in Patients with CKD. | Q36031714 |
| | Volume overload and adverse outcomes in chronic kidney disease: clinical observational and animal studies | Q36141401 |
| | Serum Trimethylamine-N-Oxide is Elevated in CKD and Correlates with Coronary Atherosclerosis Burden | Q36417895 |
| | Serum Indoxyl Sulfate Associates with Postangioplasty Thrombosis of Dialysis Grafts | Q36746081 |
| | Role of Indoxyl Sulfate as a Predisposing Factor for Atrial Fibrillation in Renal Dysfunction | Q36836055 |
| | Sudden cardiac death and dialysis patients | Q37216798 |
| | Sympathetic activation in chronic renal failure | Q37272373 |
| | Interventional management of critical limb ischemia in renal patients | Q37274760 |
| | Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients | Q37378435 |
| | Risk Assessment for Sudden Cardiac Death in Dialysis Patients | Q37801514 |
| | Atherosclerosis in CKD: differences from the general population. | Q37803336 |
| | Normal and pathologic concentrations of uremic toxins | Q38012908 |
| | Cardiorenal protective effect of the oral uremic toxin absorbent AST-120 in chronic heart disease patients with moderate CKD. | Q38467574 |
| | Future Avenues to Decrease Uremic Toxin Concentration | Q38616213 |
| | Protein-bound uremic toxins: a long overlooked culprit in cardiorenal syndrome | Q38826236 |
| | The harmful effect of indoxyl sulfate on neovascularization in chronic kidney disease | Q39994491 |
| | Phosphorylation of the endothelial nitric oxide synthase at ser-1177 is required for VEGF-induced endothelial cell migration | Q40866639 |
| | Dialysis Vascular Access Intervention and the Search for Biomarkers | Q42925625 |
| | Serum protein-bound uraemic toxins and clinical outcomes in haemodialysis patients | Q43064207 |
| | Indoxyl sulfate upregulates expression of ICAM-1 and MCP-1 by oxidative stress-induced NF-kappaB activation. | Q43100843 |
| | Does indoxyl sulfate, a uraemic toxin, have direct effects on cardiac fibroblasts and myocytes? | Q43202700 |
| | Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease | Q43241952 |
| | Association between AST-120 and abdominal aortic calcification in predialysis patients with chronic kidney disease | Q43461034 |
| | Oral charcoal adsorbent (AST-120) prevents progression of cardiac damage in chronic kidney disease through suppression of oxidative stress | Q43609975 |
| | Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure | Q43803594 |
| | Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study | Q44044868 |
| | Indolic uremic solutes increase tissue factor production in endothelial cells by the aryl hydrocarbon receptor pathway | Q44141875 |
| | Bifidobacterium in gastro-resistant seamless capsule reduces serum levels of indoxyl sulfate in patients on hemodialysis | Q44338020 |
| | Very low protein diet reduces indoxyl sulfate levels in chronic kidney disease | Q44527821 |
| | The uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair | Q44724729 |
| | Oral ADSORBENT AST-120 decreases carotid intima-media thickness and arterial stiffness in patients with chronic renal failure | Q44820468 |
| | Chronic kidney disease alters intestinal microbial flora | Q46042782 |
| | Indoxyl sulphate induces oxidative stress and the expression of osteoblast-specific proteins in vascular smooth muscle cells. | Q46150965 |
| | Indoxyl sulfate inhibits nitric oxide production and cell viability by inducing oxidative stress in vascular endothelial cells | Q46171652 |
| | Indoxyl sulfate promotes proliferation of human aortic smooth muscle cells by inducing oxidative stress. | Q46176151 |
| | All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan | Q46513688 |
| | Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis | Q46610834 |
| | Free p-cresol is associated with cardiovascular disease in hemodialysis patients | Q46729408 |
| | Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients. | Q46900369 |
| | Indoxyl sulfate predicts cardiovascular disease and renal function deterioration in advanced chronic kidney disease | Q47274327 |
| | Indoxyl sulfate suppresses endothelial progenitor cell-mediated neovascularization | Q48063950 |
| | Kidney function and risk of peripheral arterial disease: results from the Atherosclerosis Risk in Communities (ARIC) Study. | Q50795933 |
| | The uremic toxin indoxyl sulfate increases pulmonary vein and atrial arrhythmogenesis. | Q53017670 |
| | Indoxyl sulfate stimulates proliferation of rat vascular smooth muscle cells. | Q53627736 |
| | Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells | Q58816342 |
| | Nontraumatic lower extremity amputations in the Medicare end-stage renal disease population | Q60484698 |
| | Accelerated atherosclerosis in prolonged maintenance hemodialysis | Q69737869 |
| | Inhibition of the accumulation of uremic toxins in the blood and their precursors in the feces after oral administration of Lebenin, a lactic acid bacteria preparation, to uremic patients undergoing hemodialysis | Q71728826 |
| | Rats with moderate renal failure show capillary deficit in heart but not skeletal muscle | Q73686582 |
| | The protein metabolite hypothesis, a model for the progression of renal failure: an oral adsorbent lowers indoxyl sulfate levels in undialyzed uremic patients | Q73831646 |
| | Indoxyl sulphate promotes aortic calcification with expression of osteoblast-specific proteins in hypertensive rats | Q80853636 |
| | A multicenter, randomized, double-blind, placebo-controlled, dose-ranging study of AST-120 (Kremezin) in patients with moderate to severe CKD | Q82971657 |
| | Characteristics of sudden death in hemodialysis patients | Q83283477 |
| | Atrial fibrillation: the beat is faster than the answers | Q83446442 |
| | Effects of AST-120 on left ventricular mass in predialysis patients | Q83448636 |
| | Serum free p-cresyl sulfate levels predict cardiovascular and all-cause mortality in elderly hemodialysis patients--a prospective cohort study | Q84888198 |
| | In acute kidney injury, indoxyl sulfate impairs human endothelial progenitor cells: modulation by statin | Q86113659 |
| P275 | copyright license | Creative Commons Attribution-NonCommercial | Q6936496 |
| P433 | issue | 2 | |
| P921 | main subject | cardiovascular disease | Q389735 |
| | chronic renal insufficiency | Q736715 |
| | risk factor | Q1475848 |
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P577 | publication date | 2017-02-07 | |
| P1433 | published in | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease | Q19880670 |
| P1476 | title | Indoxyl Sulfate: A Novel Cardiovascular Risk Factor in Chronic Kidney Disease | |
| P478 | volume | 6 | |